

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	:	
	:	
Geiger	:	Art Unit: 1646
	:	
Serial No. 10/0568,235	:	Examiner: To be assigned
	:	
Filed: February 14, 2006	:	Atty Docket: SJ-03-0016A
	:	
For: Chimeric Receptors with Disrupted	:	
Dileucine Motifs	:	

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §1.56, Applicants wish to call the Examiner's attention to the reference nos. C2 thru C7 cited on the attached form Patent and Trademark Office form PTO/SB/08B.

A copy of the listed references are enclosed herewith in accordance with 37 CFR §1.98(a)(2).


The Examiner is respectfully requested to consider the foregoing in relation to this application including an indication thereof by making the cited references of record herein and to

indicate that the references were considered by initialing and returning a copy of the PTO-1449 form to Applicants.

In accordance with 37 C.F.R. §1.97(b)(3), no fee is believed to be required for consideration of this statement because it is being submitted prior to the mailing of a first office action on the merits. The cited documents were listed in a November 16, 2006 search report for corresponding international application PCT/US04/25930. A copy of this search report is included as document no. C2.

The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment, to Deposit Account No. 501968.

Respectfully submitted,



James Scott Elmer
Attorney for Applicant
Registration No. 36,129

St. Jude Children's Research Hospital
332 North Lauderdale
Memphis, TN 38105-2794
Telephone: 901-495-2756

Date: November 30, 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/568,235
		Filing Date	February 14, 2006
		First Named Inventor	Geiger, Terrance L.
		Art Unit	1646
		Examiner Name	Unknown
Sheet 1	of 1	Attorney Docket Number SJ-03-0016A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C2	PCT Written Opinion; November 18, 2006; 6 pages	
	C3	HAFT, C.R., et al.; "Involvement of Dileucine Motifs in the International and Degradation of the Insulin Receptor"; J Bio Chem 269:26286-26294 (1994)	
	C4	PAGES, F., et al.; "Two Distinct Intracytoplasmic Regions of the T-cell Adhesion Molecule CD28 Participate in Phosphatidylinositol 3-Kinase Association"; J Bio Chem 271:9403-9 (1996)	
	C5	GEISLER, C., et al.; "Leucine-based Receptor Sorting Motifs Are Dependent on the Spacing Relative to the Plasma Membrane"; J Biol Chem 273:21316-21323 (1998)	
	C6	TRUNEH, A., et al.; "Differential Recognition by CD28 of ITS Cognate Counter Receptors CD80 (B7.1) and B70(B7.2): Analysis by Site Directed Mutagenesis"; Mol Imm 33:321-4 (1990)	
	C7	NGUYEN, P., et al.; "Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function"; Blood 102:4320-25 (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.56. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.